ArticleThe Laryngoscope2026
Systemic Immunosuppression to Reduce Surgical Intervention in ANCA-Negative Subglottic Stenosis.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIdiopathic subglottic stenosis (iSGS) is a disease of unclear etiology and predictable phenotype. While surgical dilatation is the mainstay of management, a subset of patients experiences recurrent disease with minimal long-term symptomatic relief. This study evaluates whether systemic immunosuppression alongside surgical management is an effective adjunctive treatment strategy in this patient cohort.
methodsA retrospective study was conducted on patients at a tertiary airway center with isolated SGS. The cohort was categorized into idiopathic SGS and granulomatosis with polyangiitis SGS (GPA-SGS). A sub-cohort of iSGS patients with aggressive disease was classified as "atypical-SGS." Both atypical-SGS and GPA-SGS cohorts received systemic immunosuppression alongside surgery and disease activity was assessed before and after immunosuppression through the inter-dilation interval (IDI).
resultsSixty patients were included: 33 with iSGS, 20 with GPA-SGS, and 7 with atypical SGS. The iSGS cohort had an indolent disease course, with a median IDI of 17.6 months (IQR 16.0-25.0); none received immunosuppression. GPA-SGS patients demonstrated significantly shorter intervals prior to treatment (median 8.9 months, IQR 3.8-28.0), improving to 26.0 months (IQR 9.3-36.7) following immunosuppression (p = 0.0027). Similarly, in atypical SGS, IDI increased from 7.6 months (IQR 6.8-12.0) to 27.8 months (IQR 12.0-49.0) post-treatment (p = 0.0496). No significant adverse events were observed.
conclusionAtypical SGS represents a diagnostically ambiguous yet clinically aggressive subset of SGS. Systemic immunosuppression, typically reserved for GPA, may prolong disease-free intervals in both GPA-SGS and atypical SGS. These findings support multidisciplinary evaluation and consideration of immunotherapy in frequently recurring, ANCA-negative SGS. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.